New Negamycin-Based Potent Readthrough Derivative Effective against TGA-Type Nonsense Mutations

[Image: see text] We report a novel negamycin derivative TCP-1109 (13x) which serves as a potent readthrough drug candidate against nonsense-associated diseases. We previously demonstrated that TCP-112 (7), a nor-compound of native 3-epi-deoxynegmaycin, showed a higher readthrough activity than (+)-...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:ACS Med Chem Lett
Päätekijät: Hamada, Keisuke, Omura, Noriko, Taguchi, Akihiro, Baradaran-Heravi, Alireza, Kotake, Masaya, Arai, Misaki, Takayama, Kentaro, Taniguchi, Atsuhiko, Roberge, Michel, Hayashi, Yoshio
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Chemical Society 2019
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6792177/
https://ncbi.nlm.nih.gov/pubmed/31620232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.9b00273
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia